Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease

lncRNA *TRIB1AL* identified by GWAS plus Mendelian randomization as a hepatic MASLD regulator, independently of the neighboring coding gene *TRIB1*

A GWAS meta-analysis of 16,532 MASLD cases and 1,240,188 controls, coupled with hepatic transcriptomic analysis of 504 individuals, identified the lncRNA TRIB1AL as a novel candidate gene in metabolic steatohepatitis. Mendelian randomization demonstrated that lower hepatic TRIB1AL expression is causally associated with reduced liver fat accumulation, dyslipidemia, and cardiovascular risk. Rare loss-of-function variants in TRIB1 (neighboring coding gene) were not associated with hepatic phenotypes in the UK Biobank, confirming the lncRNA's independent effect.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The discovery of TRIB1AL illustrates the importance of the noncoding genome in hepatic metabolic pathology. The independence of this effect from TRIB1 is methodologically robust and justifies therapeutic exploration through RNA silencing. Direct diagnostic impact is limited, but therapeutic potential is real.